TG Therapeutics reports Q3 EPS $2.43, consensus 22c

Reports Q3 revenue $161.709M, consensus $152.17M. Michael Weiss, the Company’s Chairman and Chief Executive Officer, stated, “We are pleased to see that the third quarter marked another strong period of performance across our strategic priorities, driving continued BRIUMVI growth, advancing our pipeline with two Phase 3 programs, one evaluating subcutaneous ublituximab and the other evaluating asimplified BRIUMVI IV dosing schedule while maintaining a disciplined capital allocation approach. We also successfully completed our initial $100 million share repurchase program and authorized an additional $100 million program, underscoring our confidence in the long-term potential of our business.”